Insider · CIK 0001855643
Markus Warmuth
Files at GLUE (Monte Rosa Therapeutics, Inc.). First filing Jan 5, 2026, latest Jul 17, 2026.
In brief
Markus Warmuth files SEC Form 4 as CEO, president and director at GLUE (Monte Rosa Therapeutics, Inc.). Since Jan 5, 2026, Markus Warmuth has reported 0 open-market buys worth $0 and 7 open-market sells worth $951k, the latest filed on Jul 17, 2026.
A track record needs three past buys with six months of prices behind them; Markus Warmuth has 0, so none is measured yet.
The newest scored trade: sold $220k of GLUE on Jul 16, 2026, filed Jul 17, 2026, scored 52 (moderate). In the last 12 months: 0 buys worth $0 and 7 sells worth $951k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
GLUE: Monte Rosa Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 52Moderate | Monte Rosa Therapeutics, Inc. | $220k 9,500 shares | -2% | +453% from low-8% from high | |
| 30Weak | Monte Rosa Therapeutics, Inc. | $106k 5,466 shares | -1% | +369% from low-22% from high | |
| 15Weak | Monte Rosa Therapeutics, Inc. | $103k 5,467 shares | -1% | +408% from low-26% from high | |
| 44Moderate | Monte Rosa Therapeutics, Inc. | $141k 8,000 shares | -1% | +373% from low-31% from high | |
| 30Weak | Monte Rosa Therapeutics, Inc. | $98k 5,466 shares | -1% | +400% from low-27% from high | |
| 31Weak | Monte Rosa Therapeutics, Inc. | $128k 5,466 shares | -1% | +529% from low0% from high | |
| 51Moderate | Monte Rosa Therapeutics, Inc. | $154k 10,135 shares | -2% | +289% from low-23% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jul 16, 2026 | GLUE MONTE ROSA THERAPEUTICS, INC. | 9,500 0.01% of outstanding | $220k | Jul 16, 2026 | $210k |
| Jun 1, 2026 | GLUE Monte Rosa Therapeutics, Inc. | 5,466 0.01% of outstanding | $106k | Jun 1, 2026 | $343k |
| May 1, 2026 | GLUE Monte Rosa Therapeutics, Inc. | 5,467 0.01% of outstanding | $103M | May 1, 2026 | $239k |
| Apr 14, 2026 | GLUE MONTE ROSA THERAPEUTICS, INC. | 8,000 0.01% of outstanding | $141k | Apr 14, 2026 | $98k |
| Mar 2, 2026 | GLUE Monte Rosa Therapeutics, Inc. | 5,466 0.01% of outstanding | $98k | Mar 2, 2026 | $282k |
| Jan 7, 2026 | GLUE Monte Rosa Therapeutics, Inc. | 5,466 0.01% of outstanding | $128k | Jan 7, 2026 | none |
| Jan 5, 2026 | GLUE Monte Rosa Therapeutics, Inc. | 10,135 0.02% of outstanding | $154k | Jan 5, 2026 | none |
Transactions
Every row this insider has filed, 12 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 16, 2026 | GLUE Monte Rosa Therapeutics, Inc. | SOpen-market sale Common Stock | -9,500 | $23.18 | $220k | 585,038 | Jul 17, 2026 |
| Jun 1, 2026 | GLUE Monte Rosa Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -4,998 | $19.41 | $97k | 595,006 | Jun 2, 2026 |
| Jun 1, 2026 | GLUE Monte Rosa Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -468 | $19.73 | $9,232 | 594,538 | Jun 2, 2026 |
| May 1, 2026 | GLUE Monte Rosa Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -5,467 | $18.92 | $103k | 600,004 | May 5, 2026 |
| Apr 14, 2026 | GLUE Monte Rosa Therapeutics, Inc. | SOpen-market sale Common Stock | -8,000 | $17.64 | $141k | 605,471 | Apr 15, 2026 |
| Mar 2, 2026 | GLUE Monte Rosa Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -5,466 | $17.92 | $98k | 613,471 | Mar 4, 2026 |
| Jan 7, 2026 | GLUE Monte Rosa Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -3,707 | $23.24 | $86k | 620,696 | Jan 9, 2026 |
| Jan 7, 2026 | GLUE Monte Rosa Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,450 | $23.88 | $35k | 619,246 | Jan 9, 2026 |
| Jan 7, 2026 | GLUE Monte Rosa Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -309 | $24.57 | $7,593 | 618,937 | Jan 9, 2026 |
| Jan 2, 2026 | GLUE Monte Rosa Therapeutics, Inc. | AGrant or award Common Stock | +90,000 | - | - | 634,538 | Jan 5, 2026 |
| Jan 5, 2026 | GLUE Monte Rosa Therapeutics, Inc. | SOpen-market sale Common Stock | -10,135 | $15.17 | $154k | 624,403 | Jan 5, 2026 |
| Jan 2, 2026 | GLUE Monte Rosa Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +406,000 | $0.00 | $0 | 406,000 | Jan 5, 2026 |
Questions about Markus Warmuth
Answered from the filings on this page, as of the latest one.
Is Markus Warmuth buying or selling?
In the last 12 months Markus Warmuth reported 0 open-market buys worth $0 and 7 open-market sells worth $951k on SEC Form 4; the latest was sold $220k of GLUE on Jul 16, 2026. Grants, option exercises and tax withholding are not counted.
How did Markus Warmuth's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Markus Warmuth has 0.
Where does Markus Warmuth file Form 4?
Markus Warmuth has filed Form 4 at GLUE (Monte Rosa Therapeutics, Inc.) as President & CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.